Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma
Authors
Ribas, ASchachter, J
Long, G
Arance, A
Grob, Jean J
Mortier, L
Daud, A
Carlino, M
McNeil, C
Lotem, M
Larkin, J
Lorigan, Paul C
Neyns, B
Blank, C
Hamid, O
Kosh, M
Zhou, H
Ibrahim, N
Ebbinghaus, S
Robert, C
Affiliation
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CAIssue Date
2015-08-02
Metadata
Show full item recordCitation
Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma 2015, 75 (15 Supplement):CT101 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.AM2015-CT101Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2015-CT101